4th Feb 2008 07:01
Stem Cell Sciences plc04 February 2008 Press Release Stem Cell Sciences NON-EXECUTIVE BOARD CHANGE ("Stem Cell Sciences", "SCS") 4th February 2008 Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced that non-executiveDirector Jeremy Paul Scudamore, due to the increasing work load from his othernon-executive positions, has reluctantly retired from the Board of SCS effectiveJanuary 31, 2008 The Board of SCS would like to thank Mr Scudamore for his considerablecontribution to the company and wish him well with his new endeavours. - Ends - For further information, please contact: Stem Cell Sciences plc (United Kingdom)Alastair Riddell CEO+44 (0)1223 499160 Halsin Partners (United Kingdom)Michael Sinclair, Director+44 (0) 20 7084 5955 Talk Biotech (Australia)Fay Weston+61 4 2220 6036 Notes to EditorsStem Cell Sciences plc (SCS, AIM:STEM, ASX:STC) is a global biotechnologycompany providing the biological infrastructure of cells and cell culture mediato the burgeoning stem cell research market. Stem Cell Sciences' core objective is to develop safe and effective cell-basedtherapies for currently incurable diseases. SCS retains all rights to itstechnology for therapeutic use and is targeting cell-based therapies forneurodegenerative disease and injury. Revenues from Stem Cell Sciences' research business are delivered via anintegrated network of business teams and regional offices in Edinburgh andCambridge (UK), Melbourne (Australia) and San Francisco (USA). This global reachprovides the Company with the direct access to markets through experiencedpersonnel and local business networks needed to drive SCS business growth ineach region. The key challenge for the successful application of stem cells in both researchand clinical applications is the reproducible supply of pure, fullycharacterised stem cells and stem cell-derived specialised cells such as nervesand muscle. This represents a significant technological challenge that willrequire access to multiple technologies and a globally integrated stem cellinitiative. To access cutting edge technologies on a rapid and on-going basis, Stem CellSciences has built an exceptional network of highly interactive collaborationswith academic centres of excellence in the stem cell field. These collaborationshave been the source of our founding technologies and continue to provide anexpanding pipeline of products and intellectual property that are central to theCompany's strategy and success. To facilitate research and technology transfer with its major collaboratingacademic institutions, Stem Cell Sciences' business and scientific teams areusually co-located on site or adjacent to the centre of excellence inindependent company facilities. The Company's key collaborating institutesinclude the Wellcome Trust Centre for Stem Cell Research (University ofCambridge), the Institute of Stem Cell Research (University of Edinburgh), RIKENCentre for Developmental Biology (Kobe) and the Australian Stem Cell Centre(Melbourne). Academic and commercial use of stem cells in basic research and drug discoveryprovides the Company with immediate and growing revenue streams and offsets thecost of technology development for full scale cell production of SCS cell-basedtherapeutics. For further information on the company please visit: www.stemcellsciences.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SThree